that's where i come out as well. we are a small company without BLA experience, that hired a dog$#%& CRO. Amarex is clearly terrible - and we made a bad decision hiring them.

Bigger picture, we've more than doubled the indications that our drug can treat - yet the value of our company has dropped by more than half. In other words, the value of the underlying product seems much greater, but the value assigned by the market is down by 70%.

Some will say that's a function of outside forces (big pharma, FDA, etc.). I think it's simply the market not believing we can execute - do the basic blocking and tackling of submitting the BLA, or successfully completing a trial with PE being hit.

To be clear, i think we'll get there which is why i remain long. But unless i'm the only one wondering why our value has shrunk, even while we've added 20 new indications, i think it's execution.

That's why i mentioned someone like Recknor as CEO. I agree he needs to stay focused on what he's doing - but the way forward is leadership focused on execution vs. adding new indications. Hopefully we're down that path now with the new hires. Time will tell i suppose.